Masayuki Kobayashi

Dr. Masayuki Kobayashi

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Virology Journal
Verified
Journal Article
Open access
PDF file
MMMasashi Matsui
Masashi Matsui
KSKeisuke Shindo
Keisuke Shindo
Taisuke IzumiTaisuke Izumi
Taisuke Izumi
KIKatsuhiro Io
Katsuhiro Io
MSMasanobu Shinohara
Masanobu Shinohara
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
HIV-1 Vif is essential for virus replication in natural target cells such as T cells and macrophages. Vif recruits a ubiquitin ligase to degrade restrictive APOBEC3 proteins. APOBEC3G is one of the most potent retroviral restriction factors targeted by Vif and, as such, the Vif-APOBEC3G interaction has emerged as a promising HIV-1 therapeutic target.

3 April 2015 in Science Advances
Verified
Journal Article
Open access
PDF file
KTKohei Tada
Kohei Tada
MKMasayuki Kobayashi
Masayuki Kobayashi
YTYoko Takiuchi
Yoko Takiuchi
FIFumie Iwai
Fumie Iwai
TSTakashi Sakamoto
Takashi Sakamoto
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
An anti–HIV-1 drug is found to destroy leukemia cells in adults.

9 May 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HYHiroyuki Yamazaki
Hiroyuki Yamazaki
KSKotaro Shirakawa
Kotaro Shirakawa
TMTadahiko Matsumoto
Tadahiko Matsumoto
SHShigeki Hirabayashi
Shigeki Hirabayashi
YMYasuhiro Murakawa
Yasuhiro Murakawa
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) DNA cytosine deaminases have emerged as potential genomic mutators in various cancers. Multiple myeloma accumulates APOBEC signature mutations as it progresses; however, the mechanisms underlying APOBEC signature acquisition and its consequences remain elusive. In this study, we examined the significance and clinical impact of APOBEC3B (A3B) activity in multiple myeloma. Among APOBECs, only highly expressed A3B was associated with poor prognosis in myeloma patients, independent of other known poor prognostic factors. Quantitative PCR revealed that CD138-positive primary myeloma cells and myeloma cell lines exhibited remarkably high A3B expression levels. Interestingly, lentiviral A3B knockdown prevented the generation of deletion and loss-of-function mutations in exogenous DNA, whereas in control cells, these mutations accumulated with time. A3B knockdown also decreased the basal levels of γ-H2AX foci, suggesting that A3B promotes constitutive DNA double-strand breaks in myeloma cells. Importantly, among control shRNA-transduced cells, we observed the generation of clones that harboured diverse mutations in exogenous genes and several endogenous genes frequently mutated in myeloma, including TP53. Taken together, the results suggest that A3B constitutively mutates the tumour genome beyond the protection of the DNA repair system, which may lead to clonal evolution and genomic instability in myeloma.

22 November 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
TKTakahito Kawata
Takahito Kawata
KTKohei Tada
Kohei Tada
MKMasayuki Kobayashi
Masayuki Kobayashi
TSTakashi Sakamoto
Takashi Sakamoto
YTYoko Takiuchi
Yoko Takiuchi
ATAkifumi Takaori‐Kondo
Akifumi Takaori‐Kondo
Adult T‐cell leukemia (ATL) has a poor prognosis as a result of severe immunosuppression and rapid tumor progression with resistance to conventional chemotherapy. Recent integrated‐genome analysis has revealed mutations in many genes involved in the T‐cell signaling pathway, suggesting that the aberration of this pathway is an important factor in ATL pathogenesis and ATL‐cell proliferation. We screened a siRNA library to examine signaling‐pathway functionality and found that the PI3K/Akt/mTOR pathway is critical to ATL‐cell proliferation. We therefore investigated the effect of mammalian target of rapamycin (mTOR) inhibitors, including the dual inhibitors PP242 and AZD8055 and the mTORC1 inhibitors rapamycin and everolimus, on human T‐cell leukemia virus type 1 (HTLV‐1)‐infected‐cell and ATL‐cell lines. Both dual inhibitors inhibited the proliferation of all tested cell lines by inducing G1‐phase cell‐cycle arrest and subsequent cell apoptosis, whereas the effects of the 2 mTORC1 inhibitors were limited, as they did not induce cell apoptosis. In the ATL‐cell lines and in the primary ATL samples, both dual inhibitors inhibited phosphorylation of AKT at serine‐473, a target of mTORC2, as well as that of S6K, whereas the mTORC1 inhibitors only inhibited mTORC1. Furthermore, AZD8055 more significantly inhibited the in vivo growth of the ATL‐cell xenografts than did everolimus. These results indicate that the PI3K/mTOR pathway is critical to ATL‐cell proliferation and might thus be a new therapeutic target in ATL.

5 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TMTadahiko Matsumoto
Tadahiko Matsumoto
KSKotaro Shirakawa
Kotaro Shirakawa
MYMasaru Yokoyama
Masaru Yokoyama
HFHirofumi Fukuda
Hirofumi Fukuda
ASAnamaria Daniela Sarca
Anamaria Daniela Sarca
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
APOBEC3B cytidine deaminase (A3B) catalyzes cytosine into uracil in single-strand DNA and induces C-to-T mutations in genomic DNA of various types of tumors. Accumulation of APOBEC signature mutations is correlated with a worse prognosis for patients with breast cancer or multiple myeloma, suggesting that A3B activity might be a cause of the unfavorable DNA mutations and clonal evolution in these tumors. Phosphorylation of conserved threonine residues of other cytidine deaminases, activation induced deaminase (AID) and APOBEC3G, inhibits their activity. Here we show that protein kinase A (PKA) physically binds to A3B and phosphorylates Thr214. In vitro deaminase assays and foreign DNA editing assays in cells confirm that phosphomimetic A3B mutants, T214D and T214E, completely lose deaminase activity. Molecular dynamics simulation of A3B phosphorylation reveals that Thr214 phosphorylation disrupts binding between the phospho-A3B catalytic core and ssDNA. These mutants still inhibit retroviral infectivity at least partially, and also retain full anti-retrotransposition activity. These results imply that PKA-mediated phosphorylation inhibits A3B mutagenic activity without destructing its innate immune functions. Therefore, PKA activation could reduce further accumulation of mutations in A3B overexpressing tumors.

17 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TSTakashi Sakamoto
Takashi Sakamoto
MKMasayuki Kobayashi
Masayuki Kobayashi
KTKohei Tada
Kohei Tada
MSMasanobu Shinohara
Masanobu Shinohara
KIKatsuhiro Io
Katsuhiro Io
ATAkifumi Takaori-Kondo
Akifumi Takaori-Kondo
The transcription factor NF-κB plays a key regulatory role in lymphocyte activation and generation of immune response. Stimulation of T cell receptor (TCR) induces phosphorylation of CARMA1 by PKCθ, resulting in formation of CARMA1-Bcl10-MALT1 (CBM) complex at lipid rafts and subsequently leading to NF-κB activation. While many molecular events leading to NF-κB activation have been reported, it is less understood how this activation is negatively regulated. We performed a cell-based screening for negative regulators of TCR-mediated NF-κB activation, using mutagenesis and complementation cloning strategies. Here we show that casein kinase-2 interacting protein-1 (CKIP-1) suppresses PKCθ-CBM-NF-κB signaling. We found that CKIP-1 interacts with CARMA1 and competes with PKCθ for association. We further confirmed that a PH domain of CKIP-1 is required for association with CARMA1 and its inhibitory effect. CKIP-1 represses NF-κB activity in unstimulated cells, and inhibits NF-κB activation induced by stimulation with PMA or constitutively active PKCθ, but not by stimulation with TNFα. Interestingly, CKIP-1 does not inhibit NF-κB activation induced by CD3/CD28 costimulation, which caused dissociation of CKIP-1 from lipid rafts. These data suggest that CKIP-1 contributes maintenance of a resting state on NF-κB activity or prevents T cells from being activated by inadequate signaling. In conclusion, we demonstrate that CKIP-1 interacts with CARMA1 and has an inhibitory effect on PKCθ-CBM-NF-κB signaling.